ABSI

Absci Corp

Add to Watchlist

Advanced Chart

2.970

+0.12(4.211%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.010

Open

2.900

VWAP

2.93

Vol

5.21M

Mkt Cap

428.31M

Low

2.860

Amount

15.26M

EV/EBITDA(TTM)

Total Shares

113.08M

280.28M

EV/OCF(TTM)

P/S(TTM)

68.95

Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.

Get winning stock picks in minutes

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

2.73M

+310.25%

-0.193

-22.86%

4.65M

+173.34%

-0.196

-18.45%

1.21M

-4.39%

-0.209

-5.2%

Estimates Revision

The market is revising Downward the revenue expectations for Absci Corporation (ABSI) for FY2025, with the revenue forecasts being adjusted by -10.75% over the past three months. During the same period, the stock price has changed by 0.34%.

Revenue Estimates for FY2025

Revise Downward

-10.75%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-10.79%

In Past 3 Month

Stock Price

Go Up

+0.34%

In Past 3 Month

7 Analyst Rating

205.39% Upside

Wall Street analysts forecast ABSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABSI is 9.07 USD with a low forecast of 6.40 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

205.39% Upside

Current: 2.970

Low

6.40

Averages

9.07

High

13.00

205.39% Upside

Current: 2.970

Low

6.40

Averages

9.07

High

13.00

Morgan Stanley

Overweight

downgrade

2025-07-27

Reason

Morgan Stanley

Price Target

2025-07-27

downgrade

Overweight

Reason

Morgan Stanley lowered the firm's price target on Absci to $6.40 from $7 and keeps an Overweight rating on the shares after the company announced a $50M public offering. The firm modeled a new share count and cash.

Morgan Stanley

Overweight

initiated

2025-07-03

Reason

Morgan Stanley

Price Target

2025-07-03

initiated

Overweight

Reason

Morgan Stanley assumed coverage of Absci with an Overweight rating and $7 price target. Absci has faced volatility due to a combination of macroeconomic factors, underperformance on initial clinical results and uncertainty on valuation and revenue drivers, the analyst tells investors in a research note. The upcoming value inflection points with the second half of 2025 interim data readout for TL1A asset ABS-101 and second half of 2026 Phase I interim proof of concept efficacy readout for PRLR ABS-201 present potential results skewed to the upside for Absci, the firm says.

Keybanc

Scott Schoenhaus

Buy

Maintains

$5 → $9

2025-04-16

Reason

Keybanc

Scott Schoenhaus

Price Target

$5 → $9

2025-04-16

Maintains

Buy

Reason

KeyBanc raised the firm's price target on Absci to $9 from $5 and keeps an Overweight rating on the shares. Into Q1 earnings, the firm believes the focus for the HCIT sector will be on legislative policies, healthcare system utilization, and macro concerns on a slowing economy paired with potentially higher inflation. While valuations in HCIT land remain discounted vs. healthcare more broadly, KeyBanc thinks investors should be focused on companies that can drive meet/beats over the next 12 months. Specifically, it sees the least risk from a revenue and earnings perspective from companies that are well positioned in the more stable healthcare end markets serving the payers and large pharma.

Needham

Gil Blum

Strong Buy

Reiterates

2025-04-09

Reason

Needham

Gil Blum

Price Target

2025-04-09

Reiterates

Strong Buy

Reason

Guggenheim

Vamil Divan

Strong Buy

Reiterates

$10

2025-03-20

Reason

Guggenheim

Vamil Divan

Price Target

$10

2025-03-20

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

2025-03-19

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

2025-03-19

Reiterates

Strong Buy

Reason

See All Ratings

Get winning stock picks in minutes

Valuation Metrics

The current forward P/E ratio for Absci Corp (ABSI.O) is -3.70, compared to its 5-year average forward P/E of -5.72. For a more detailed relative valuation and DCF analysis to assess Absci Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.72

Current PE

-3.70

Overvalued PE

0.03

Undervalued PE

-11.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.75

Current EV/EBITDA

-2.22

Overvalued EV/EBITDA

2.62

Undervalued EV/EBITDA

-12.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

44.19

Current PS

28.30

Overvalued PS

86.70

Undervalued PS

1.68